Efficacy evaluation of standardized dust mite allergen specific immunotherapy to patients of allergic rhinitis / 临床耳鼻咽喉头颈外科杂志

ABSTRACT

OBJECTIVE@#To evaluate the efficacy of mite allergen specific immunotherapy (SIT) to patients of allergic rhinitis.@*METHOD@#A total of 102 patients with mite allergy were recruited into the study. They were randomly divided into two groups SIT group (n = 51) and ST (symptomatic therapy) group (n = 51). They were given SIT with standardized allergen vaccine for 3 years or only symptomatic therapy respectively. Observation items include rhinitis symptom scores, drug score, skin prick test result, serum specificity IgE (sIgE), peripheral eosinophil counting. The development of asthma and new allergens sensitization was also assessed.@*RESULT@#The blood eosinophil numbers, skin test index, rhinitis symptom scores and drug scores were all decreased significantly after the treatment with SIT for 3 years compared to that of ST group (P < 0.01). Although the level of serum slgE was decreased, no statistic diferences were found. No patients developed asthma in SIT group, and only 2.1% of patients had new allergen sensitization; 17.4% of those in ST group developed asthma, 32.6% had new sensitization. No severe adverse events occurred.@*CONCLUSION@#Keeping long-term SIT is effective and safe for patients with allergic rhinitis induced by mite, which can also prevent new allergen sensitization and development for asthma.